Brief: Immuneonco Biopharmaceuticals Shanghai Gets Orphan-Drug Designation From FDA
08/11/2023 15:14
Nov 8 (Reuters) - ImmuneOnco Biopharmaceuticals Shanghai
Inc 1541.HK :
* ORPHAN-DRUG DESIGNATION FROM FDA IN RESPECT OF COMBINATION
OF
IMM01 AND AZACITIDINE FOR TREATMENT OF CMML
Source text for Eikon: ID:
Further company coverage: 1541.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ImmuneOnco Biopharmaceuticals (Shanghai)
See all newsBrief: Immuneonco Biopharmaceuticals (Shanghai) To Subscribe For Wealth Management Product For Hk$87.5 Million
Brief: ImmuneOnCo Biopharmaceuticals (Shanghai) To Repurchase H Shares In Open Market
Brief: Immuneonco Biopharmaceuticals (Shanghai)Subscribes For Hk$212 Million Wealth Management Product
Brief: Immuneonco Biopharmaceuticals Shanghai Inc Posts FY Loss Attributable RMB218.6 Million
Brief: ImmuneOnco Biopharmaceuticals Shanghai Receives Approval From NMPA China For Investigational New Drug Application Of IMM0306S